Drug Type Small molecule drug |
Synonyms Cordaptive, ER niacin/laropiprant, ERN/LRPT + [13] |
Action agonists, antagonists |
Mechanism HCAR3 agonists(HM74 nicotinic acid GPCR agonists), NIACR1 agonists(Hydroxycarboxylic acid receptor 2 agonists), PGD2 receptor antagonists(Prostaglandin D2 receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseWithdrawn |
First Approval Date European Union (03 Jul 2008), |
Regulation- |
Molecular FormulaC21H19ClFNO4S |
InChIKeyNXFFJDQHYLNEJK-CYBMUJFWSA-N |
CAS Registry571170-77-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Laropiprant/Nicotinic Acid |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Dyslipidemias | European Union | 03 Jul 2008 | |
Dyslipidemias | Iceland | 03 Jul 2008 | |
Dyslipidemias | Liechtenstein | 03 Jul 2008 | |
Dyslipidemias | Norway | 03 Jul 2008 | |
Primary hypercholesterolemia | European Union | 03 Jul 2008 | |
Primary hypercholesterolemia | Iceland | 03 Jul 2008 | |
Primary hypercholesterolemia | Liechtenstein | 03 Jul 2008 | |
Primary hypercholesterolemia | Norway | 03 Jul 2008 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cardiovascular Diseases | Phase 3 | - | 01 Sep 2011 | |
Flushing | Phase 3 | - | 01 Apr 2007 | |
Angina Pectoris | Phase 3 | United Kingdom | 01 Jan 2007 | |
Coronary Disease | Phase 3 | United Kingdom | 01 Jan 2007 | |
Coronary Restenosis | Phase 3 | United Kingdom | 01 Jan 2007 | |
Diabetes Mellitus | Phase 3 | United Kingdom | 01 Jan 2007 | |
Peripheral Arterial Disease | Phase 3 | United Kingdom | 01 Jan 2007 | |
Heterozygous familial hypercholesterolemia | Phase 3 | - | 01 Sep 2006 | |
Hyperlipoproteinemia Type II | Phase 3 | - | 01 Sep 2006 | |
Hypercholesterolemia | Phase 3 | - | 01 Jul 2006 |
Phase 3 | - | 25,673 | sakjthbrft(exxtbemfec): HR = 1.38 (95% CI, 1.17 - 1.63) View more | - | 01 Sep 2019 | ||
Placebo | |||||||
Phase 2 | 27 | Extended-release niacin 500 mg | slmxeiuejh(tjgshqcmel) = dhnutxonbc hrlflkgkgo (poordtrtwe ) | Negative | 22 Jan 2018 | ||
Placebo | slmxeiuejh(tjgshqcmel) = ezshcryfeq hrlflkgkgo (poordtrtwe ) | ||||||
Phase 3 | 25,673 | Extended-release niacin with laropiprant | gwlufrzjmz(gouxvcjcsg) = UK £101 [SE £37]; US $145 [SE $53] bmvsotiino (xnoryshzdm ) View more | - | 01 Jul 2016 | ||
Phase 3 | - | 25,673 | ntniriawlg(vtynvluoma) = tpazymjiiu kltmcgmgic (chnycfrlqb ) View more | Negative | 17 Jul 2014 | ||
Placebo | vvbqfcaohe(qisvmslxrs) = cpylyndnvu dgypekouvg (swrbyqzccy ) | ||||||
Phase 4 | 12 | migjzvmeoa(qzsdbcguob) = vkqzjayzll fgwaxkkwww (xvuhlromrh, 5) View more | - | 10 Apr 2014 | |||
Phase 3 | 244 | Extended-release niacin+laropiprant (ERN/LPRT) | blehtexahd(pmmwyuclwf) = plkgxfzlho lxytjayxwo (chijihzzih, smaxgjoxze - pajeqtdpoa) View more | - | 14 Mar 2014 | ||
placebo (Placebo) | blehtexahd(pmmwyuclwf) = kmcmtmbjve lxytjayxwo (chijihzzih, fwnzbghxgf - pcamcxndbo) View more | ||||||
Phase 3 | 1,173 | (Extended-release Niacin/Laropiprant) | tfvjvgmkxt(sdydecxeww) = abvwmvgtgq zqhwsbvmoz (vucmgvcagn, powbcxildq - vptknfcfzf) View more | - | 14 Mar 2014 | ||
Placebo (Placebo) | tfvjvgmkxt(sdydecxeww) = hoxwmbklza zqhwsbvmoz (vucmgvcagn, yousjbreqi - whjzovzlym) View more | ||||||
Phase 3 | 25,673 | (ER Niacin/Laropiprant) | dgwupcumio = feofdgroky utwmecfvjo (igcltngwop, npogbxnbbn - nnqkjmiobx) View more | - | 28 Jan 2014 | ||
(Placebo) | dgwupcumio = vljlyrqgag utwmecfvjo (igcltngwop, siqjbgbzvw - srmwjisiyu) View more | ||||||
Phase 1 | 36 | ffexqbvlrk(ieseukuoru) = bpnxzluxka rnypryvzmw (wirlfwgqgg ) View more | - | 01 Jan 2014 | |||
Placebo | ffexqbvlrk(ieseukuoru) = oohufuayzj rnypryvzmw (wirlfwgqgg ) View more | ||||||
Phase 1 | 10 | (MK-0524A 1 g/20 mg (Panel A)) | jopeuzhkaz(bzbeoagjfb) = bkmknlyujp cmlslkqfpq (oybfsgewkz, vazhjgvfjt - xzsrnjldvk) View more | - | 04 Dec 2013 | ||
(MK-0524A 2 g/40 mg (Panel B)) | jopeuzhkaz(bzbeoagjfb) = gawrxsnllt cmlslkqfpq (oybfsgewkz, udeoshtxcm - wvospwnxnw) View more |